BioSpace News Archive

Schrödinger today announced that management will participate in the following conferences in March.

enVVeno Medical Corporation today announced that topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 American Venous Forum (AVF) Annual Meeting being held March 3-6, 2024 in Tampa, Florida.

Cannabis Bioscience International Holdings, a Houston-based company trading on the OTC Markets under the ticker symbol CBIH, has engaged the services of Bull in Advantage as its Investor Relations firm.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on Monday, March 4, 2024 at the close of the U.S. financial markets.

IR-MED Inc. reported highly favorable proof of efficacy data for PressureSafe™, its decision support device which uses infra-red spectroscopy combined with an AI-based algorithm, for the early, non-invasive, and skin color agnostic detection of pressure injuries.

Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”) is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.

Eli Lilly and Company (NYSE: LLY) will participate in Cowen’s 44th Annual Health Care Conference on March 6, 2024.

Brain-based impairments in memory, reasoning and planning – collectively known as cognitive deficits – are present in several major neuropsychiatric disorders, most notably schizophrenia, affective disorders, autism spectrum disorders and attention-deficit/hyperactivity disorder.

Biofrontera Inc. today announced the restructuring of agreements between the Company and its former parent company Biofrontera AG.